Transcell has pioneered an innovative and revolutionary animal-free testing strategy (patent protected) to implement as Digital Animal Replacement Technology (DART) – An Enterprise Solution. This technology is designed to be easily adopted by global bio/pharma companies at various stages of their discovery and development functions. It aligns with the recent FDA Modernization Act 2.0 and the international ban on testing cosmetics on animals, encouraging the use of non-animal cruelty-free testing platforms
Key features of this offering include:
- The use of AI/ML-powered digital workstations with prediction models to automate safety or efficacy tests
- Stem cell-based MicroPhysiological in vitro systems that produce human-relevant readouts as clinical surrogate data points when treated with test agents
- Integration into the end-user’s existing workflows to support discovery, development, and manufacturing processes
- Benefits such as phasing out animal testing protocols and building a brand as an ethical organization
- Alignment with the 3Rs in animal testing (Replace, Reduce, Refine)
- Assays offered as modules under a single Application Programming Interface
-
Demonstrated to support
- Screening – Phenotype Based – Libraries/Hits
- Screening – Lead molecules
- Potency Assessments
- Safety Pharmacology Testings
- Immunogenicity-Antigenicity Assessment
- Biologics Testings
- Ex vivo Clinical Trials
- Product Potency Measurement
- In vitro Pharmacology Assays in Drug Development
DART: An Animal-Free Testing Alternative
No Comments
Sorry, the comment form is closed at this time.